Should I Buy SNSE? SNSE 2026 Analysis

Should You Buy Sensei Biotherapeutics Inc (SNSE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

9.660

1 Day change

-4.17%

52 Week Range

18.350

Analysis Updated At

2026/01/26

Sensei Biotherapeutics Inc (SNSE) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent downgrades, lack of positive catalysts, poor financial performance, and absence of strong trading signals suggest that this stock does not align with the user's investment goals.

Technical Analysis

The technical indicators for SNSE show a bearish trend. The MACD is negative and expanding, RSI is neutral at 48.99, and moving averages are converging, indicating no clear upward momentum. The stock is trading below the pivot level (10.764), with support at 9.74 and resistance at 11.788.

Options Data

Positive Catalysts

NULL identified. There are no recent news events or significant positive developments.

Neutral/Negative Catalysts

The company announced plans to discontinue development of solnerstotug and initiate a review of strategic alternatives. Analysts downgraded the stock to Neutral, citing disappointment in the shelved project. Additionally, the financial performance is weak, with significant YoY declines in net income and EPS.

Financial Performance

In Q3 2025, the company reported zero revenue growth (0% YoY), a net income drop of -37.01% YoY to -$4,569,000, and an EPS decline of -37.26% YoY to -3.62. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright downgraded SNSE to Neutral from Buy on October 30, 2025, without a price target. The downgrade followed the company's announcement to discontinue a key project, with the firm expressing disappointment and moving to the sidelines pending future updates.

Analyst Rating

Wall Street analysts forecast SNSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNSE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 10.080

Low

Averages

High

Current: 10.080

Low

Averages

High

H.C. Wainwright

Buy -> Neutral

downgrade

AI Analysis

2025-10-30

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-10-30

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Sensei Biotherapeutics to Neutral from Buy.

H.C. Wainwright

Buy -> Neutral

downgrade

2025-10-30

Reason

H.C. Wainwright

Price Target

2025-10-30

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Sensei Biotherapeutics to Neutral from Buy without a price target. The company this morning announced plans to discontinue development of solnerstotug and initiate a review of strategic alternatives, the analyst tells investors in a research note. The firm moves the sidelines pending future clinical or business development updates. H.C. Wainwright is "disappointed" by solnerstotug being shelved.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SNSE

Unlock Now

SNSE Should I Buy

SNSE Should I Buy

Should You Buy Sensei Biotherapeutics Inc (SNSE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch